More on RLMD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.46 |
|
|||
| Open | $5.47 | ||||
| 52 Wk High | $4.10 | ||||
| 52 Wk Low | $0.87 | ||||
| Day High | $5.70 | ||||
| Day Low | $5.18 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,236,470 | ||||
- Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes
- Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
- H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)
- Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC
- Form S-8 RELMADA THERAPEUTICS,
- H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12
- Relmada appoints Michael Quirk as senior advisor for sepranolone program
- Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
- Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Venrock Healthcare Capital Partners III, L.P.
Entities mentioned with RLMD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
